The NDA submission for darovasertib is the key near-term catalyst; FDA review under RTOR could yield a decision in H1 2027. The OptimUM-010 closure removes a cash drain and signals capital reallocation toward IDE849 and IDE892 registrational trials. Watch for initial IDE849 Phase 1/2 data by end of 2026 or early 2027 and the R&D Day on November 16 for preclinical MTAP/KRAS data.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $31.33entry
- T+1 · 13d ago +3.29%α +1.64% · $32.36
- T+5 · 7d ago +1.34%α +1.93% · $31.75
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
The company completed its NDA submission for darovasertib in metastatic uveal melanoma and announced the closure of the Phase 3 OptimUM-010 trial, expected to save $100-125M for reallocation to other pipeline programs. Cash stood at $1.15B with runway into 2030 unchanged.
Key Financial Metrics
Key Facts
- Collaboration revenue of $10.2M for Q3 2026, up from $8.9M in Q2 2026
- Cash, cash equivalents and marketable securities of $1.15B as of September 30, 2026
- NDA submitted to FDA for darovasertib plus crizotinib in metastatic uveal melanoma under RTOR program
- Phase 3 OptimUM-010 trial closed due to enrollment challenges, expected cost savings of $100-125M
- Plans to initiate two Phase 3 registrational trials for IDE849 in ES-SCLC and NEC by year end
- R&D expenses of $121.6M for Q3 2026, up from $108.7M in Q2 2026
- G&A expenses of $26.3M for Q3 2026, up from $22.5M in Q2 2026
- Cash runway guidance into 2030 unchanged
Financial Impact
Net loss widened to $125.7M in Q3 2026 from $112.5M in Q2 2026; cash burn of ~$90M from $1.24B to $1.15B; $100-125M in cost savings from trial closure to be reallocated
Risk Factors
- FDA may not approve darovasertib NDA or may require additional data
- IDE849 Phase 3 trials may face enrollment or efficacy challenges
- Cash burn rate is increasing with R&D and G&A expenses rising quarter-over-quarter
- Competition from other DLL3-targeted therapies (e.g., tarlatamab) could limit IDE849's market opportunity
- OptimUM-010 closure may signal broader enrollment difficulties across the pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-444225 |
| Document: idya-20261103.htm | 0001193125-26-444225 |
| Document: 0001193125-26-444225-index-headers.html | 0001193125-26-444225 |
| Document: 0001193125-26-444225-index.html | 0001193125-26-444225 |
| Document: 0001193125-26-444225.txt | 0001193125-26-444225 |
| 8-K Data (Synthetic) | 0001193125-26-444225 |
Track record
13 reports on IDYA
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Viewing Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers